Claims for Patent: 10,429,379

Summary for Patent: 10,429,379

Title:	Autoantigens for diagnosis of rheumatoid arthritis
Abstract:	Disclosed herein are methods of diagnosing Rheumatoid arthritis in a subject comprising determining whether the subject is immunologically reactive with N-acetylglucosamine-6-sulfatase and/or filamin-A, wherein immunological reactivity of the subject to one or more of N-acetylglucosamine-6-sulfatase or filamin-A, as compared to an appropriate control, indicates the subject has rheumatoid arthritis. Examples of specific assays and kits for use with the methods are also disclosed.
Inventor(s):	Steere; Allen C. (Wellesley, MA), Drouin; Elise E. (Boston, MA)
Assignee:	THE GENERAL HOSPITAL CORPORATION (Boston, MA)
Application Number:	15/571,734
Patent Claims:	1. A method of treating rheumatoid arthritis in a subject comprising: (a) receiving the results of an assay that indicates an increase in the level of IFN.gamma. secretion and/or T cell proliferation following contact of a biological sample from the subject with one or more of filamin-A and N-acetylglucosamine-6-sulfatase whole protein or polypeptide fragments compared with an appropriate control sample; or (b) receiving the results of an assay that indicates an increase in the level of immunocomplexes following contact of a biological sample from the subject with one or more of filamin-A and N-acetylglucosamine-6-sulfatase, whole protein or polypeptide fragments compared to an appropriate control sample; and (c) administering to the subject one or more of a nonsteroidal anti-inflammatory drug (NSAIDs), a steroid, a disease modifying anti-rheumatic drug (DMARD), adalimumab, etanercept, abatacept, anakinra, cimzia, golimumab, infliximab, tocilizumab and tofacitinib. 2. The method of claim 1, wherein the subject has been or is further tested for one or more of rheumatoid factor, anti-citrullinated protein antibodies (ACPA), and one or more HLA-DR alleles. 3. The method of claim 1, wherein the subject is at risk for, or is suspected of having, rheumatoid arthritis. 4. The method of claim 1, wherein prior to step (a) the biological sample is obtained from a subject at risk for, suspected of having or has rheumatoid arthritis. 5. The method of claim 1, wherein the biological sample is peripheral blood, serum, synovial tissue, synovial fluid, peripheral blood mononuclear cells (PBMC), or synovial fluid mononuclear cells (SFMC) from the subject. 6. The method of claim 1, wherein the appropriate control is a biological sample from a healthy subject. 7. The method of claim 2, wherein the HLA-DR allele is HLA-DRB1*0101 and/or HLA-DRB1*0401, and/or HLA-DRB1*0405, and/or HLA-DRB1*0408, and/or HLA-DRB1*1501. 8. The method of claim 1, wherein the polypeptide fragment of filamin-A comprises the amino acid sequence NPAEFVVNTSNAGAG (SEQ ID NO: 1) or an antigenic portion thereof. 9. The method of claim 1, wherein the polypeptide fragment of N-acetylglucosamine-6-sulfatase comprises the amino acid sequence of FEPFFMMIATPAPH (SEQ ID NO: 2) or an antigenic portion thereof. 10. The method of claim 1, wherein the assay in step (b) is an enzyme-linked immunosorbent assay (ELISA), agglutination test, direct immunofluorescence assay, indirect immunofluorescence assay, or an immunoblot assay. 11. The method of claim 1, wherein the assay in step (a) is an immunospot test or proliferation assay. 12. The method of claim 1, wherein the results received are of step (b) and the assay of step (b) comprises: (a) contacting a biological sample with filamin-A protein or a polypeptide fragment thereof; and/or (b) contacting a biological sample with N-acetylglucosamine-6-sulfatase protein or a polypeptide fragment thereof; and (c) detecting an increase in the level of immunocomplexes of an antibody in the biological sample with the filamin-A protein or polypeptide fragment thereof or N-acetylglucosamine-6-sulfatase protein or polypeptide fragment thereof.

Details for Patent 10,429,379

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2035-05-12
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2035-05-12
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2035-05-12
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2035-05-12
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007		2035-05-12
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	09/14/2017		2035-05-12